In its order, the court noted that Abbott would not suffer any irreparable injury, and that an equitable assessment of this case clearly supports an end to the injunction.
Medtronic has abided by the injunction since it was originally issued in 2000, and will continue to do so until October 29, 2008. Until that time Medtronic remains enjoined from manufacture, use, offer for sale or sale, within the United States, of any Rapid Exchange catheter which infringes claim three of the ‘233 patent.
Medtronic will announce its commercial intent related to the use of Rapid Exchange technology after the injunction terminates on October 29, 2008.
ABOUT MEDTRONIC
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 25, 2008. Actual results may differ materially from anticipated results.
Contact:
Medtronic, Inc. Daniel Beach, 763-505-2603 Public Relations Jeff Warren, 763-505-2696 Investor Relations
Source: Medtronic, Inc.
